Daniel García

Dr. Daniel García

CONACYT - Universidad Autónoma de Aguascalientes

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 November 2024 in Gut Microbes
Verified
Journal Article
Open access
MRMarcela Rios-Carlos
Marcela Rios-Carlos
DGDaniel García
Daniel García
LCLaura E Córdova-Dávalos
Laura E Córdova-Dávalos
Luis Bermudez HumaránLuis Bermudez Humarán
Luis Bermudez Humarán
Eva SalinasEva Salinas
Eva Salinas
Gut microbiota exert functions of high importance in the intestine. Furthermore, there is increasing evidence for its role in immune regulation and maintenance of homeostasis in many physiological processes taking place in distant tissues. In particular, in this review, we explore the impact of metabolites produced by the gut microbiota on the development of atopic dermatitis (AD). Probiotics and prebiotics balance the microbiota and promote the generation of bacterial metabolites, such as short-chain fatty acids and tryptophan derivates, which promote the regulation of the exacerbated AD immune response through regulatory T cells and IL-10 and TGF-β cytokines. Metabolites also have a direct action on keratinocytes once they reach the bloodstream. Besides, probiotics decrease the levels of metabolites associated with AD onset, such as phenols. Understanding all these crosstalk processes between the gut and the skin reveals a number of possibilities, mainly through the manipulation of the gut microbiome, which may represent therapeutic strategies that can contribute to the standard treatments of AD patients to improve their quality of life.

Verified
Journal Article
Open access
PDF file
Pamela Gallegos-AlcaláPamela Gallegos-Alcalá
Pamela Gallegos-Alcalá
MJMariela Jiménez
Mariela Jiménez
DGDaniel García
Daniel García
Eva SalinasEva Salinas
Eva Salinas
The keratinocyte (KC) is the main functional and structural component of the epidermis, the most external layer of the skin that is highly specialized in defense against external agents, prevention of leakage of body fluids and retention of internal water within the cells. Altered epidermal barrier and aberrant KC differentiation are involved in the pathophysiology of several skin diseases, such as atopic dermatitis (AD). AD is a chronic inflammatory disease characterized by cutaneous and systemic immune dysregulation and skin microbiota dysbiosis. Nevertheless, the pathological mechanisms of this complex disease remain largely unknown. In this review, we summarize current knowledge about the participation of the KC in different aspects of the AD. We provide an overview of the genetic predisposing and environmental factors, inflammatory molecules and signaling pathways of the KC that participate in the physiopathology of the AD. We also analyze the link among the KC, the microbiota and the inflammatory response underlying acute and chronic skin AD lesions.

18 May 2020 in Molecules
Verified
Journal Article
Open access
PDF file
DGDaniel García
Daniel García
ABArmida I. Bahena-Delgado
Armida I. Bahena-Delgado
MJMariela Jiménez
Mariela Jiménez
LCLaura E. Córdova-Dávalos
Laura E. Córdova-Dávalos
VPVanessa Ruiz-Esparza Palacios
Vanessa Ruiz-Esparza Palacios
Eva SalinasEva Salinas
Eva Salinas
Nonsteroidal anti-inflammatory drug (NSAID)-induced enteropathy is considered a serious and increasing clinical problem without available treatment. Glycomacropeptide (GMP) is a 64-amino acid peptide derived from milk κ-casein with numerous biological activities. The aim of this study was to investigate the protective effect of GMP on NSAID enteropathy in rats. Enteropathy was induced by seven days oral indomethacin administration. Rats were orally GMP treated from seven days previous and during the establishment of the enteropathy model. Changes in metabolism, hematological and biochemical blood alterations, intestinal inflammation and oxidative damage were analyzed. Integrity barrier markers, macroscopic intestinal damage and survival rate were also evaluated. GMP treatment prevented anorexia and weight loss in animals. Furthermore, prophylaxis with GMP ameliorated the decline in hemoglobin, hematocrit, albumin and total protein levels. The treatment had no therapeutic efficacy on the decrease of occludin and mucin (MUC)-2 expression in intestinal tissue. However, GMP markedly decreased neutrophil infiltration, and CXCL1, interleukin-1β and inducible nitric oxide synthase expression. Nitric oxide production and lipid hydroperoxide level in the small intestine were also diminished. These beneficial effects were mirrored by preventing ulcer development and increasing animal survival. These results suggest that GMP may protect against NSAID enteropathy through anti-inflammatory and antioxidant properties.

18 July 2021 in Pathogens
Verified
Journal Article
Open access
PDF file
Estela Ruiz-BacaEstela Ruiz-Baca
Estela Ruiz-Baca
Armando Perez-TorresArmando Perez-Torres
Armando Perez-Torres
Yolanda Romo LozanoYolanda Romo Lozano
Yolanda Romo Lozano
DGDaniel García
Daniel García
CFCarlos Antonio Alba Fierro
Carlos Antonio Alba Fierro
CTConchita Toriello
Conchita Toriello
The role of immune cells associated with sporotrichosis caused by Sporothrix schenckii is not yet fully clarified. Macrophages through pattern recognition receptors (PRRs) can recognize pathogen-associated molecular patterns (PAMPs) of Sporothrix, engulf it, activate respiratory burst, and secrete pro-inflammatory or anti-inflammatory biological mediators to control infection. It is important to consider that the characteristics associated with S. schenckii and/or the host may influence macrophage polarization (M1/M2), cell recruitment, and the type of immune response (1, 2, and 17). Currently, with the use of new monocyte-macrophage cell lines, it is possible to evaluate different host–pathogen interaction processes, which allows for the proposal of new mechanisms in human sporotrichosis. Therefore, in order to contribute to the understanding of these host–pathogen interactions, the aim of this review is to summarize and discuss the immune responses induced by macrophage-S. schenckii interactions, as well as the PRRs and PAMPs involved during the recognition of S. schenckii that favor the immune evasion by the fungus.

11 January 2016 in Inflammation Research
Verified
Journal Article
Closed access
PDF file
NRNuria Renata Roldán
Nuria Renata Roldán
MJMariela Jiménez
Mariela Jiménez
DGDaniel García
Daniel García
EMEstefanía Marín
Estefanía Marín
Eva SalinasEva Salinas
Eva Salinas

25 September 2020 in Nutrients
Verified
Journal Article
Open access
PDF file
DRDiana Reyes-Pavón
Diana Reyes-Pavón
DGDaniel García
Daniel García
Luis Bermudez HumaránLuis Bermudez Humarán
Luis Bermudez Humarán
LCLaura Elena Córdova-Dávalos
Laura Elena Córdova-Dávalos
AQAndrés Quintanar-Stephano
Andrés Quintanar-Stephano
Eva SalinasEva Salinas
Eva Salinas
Glycomacropeptide (GMP) is a bioactive peptide derived from milk κ-casein with immune-modulatory and anti-inflammatory properties. Food allergy (FA) is an adverse immune reaction with a broad spectrum of manifestations. Allergen intake induces persistent intestinal inflammation and tissue damage. In this study, the anti-allergic activity of GMP was evaluated using a rat ovalbumin (OVA)-induced FA model with gastrointestinal manifestation. Rats were orally GMP treated from 3 days prior and during FA development. The severity of food anaphylaxis and diarrheal episodes, antibody production and histamine level were measured. Histopathological changes, inflammation and predominant cytokine profile at intestine were analyzed. Oral GMP intake decreased clinical signs and diarrhea severity induced by allergen, with a significant reduction in intestinal edema and expression level of IL-1β and TNF-α. Prophylaxis with GMP also diminished serum anti-OVA IgE and IgG1, and histamine levels. GMP treatment markedly decreased eosinophil infiltration, mast cell and goblet cell hyperplasia, total IgE expression in intestine, and prevented histological changes in villi, crypts and internal muscularis layer. The treatment effectively suppressed IL-5, IL-13 and GATA3 expression and skewed the intestinal cytokine profile toward type 1 and regulatory. These results suggest that GMP may protect against FA through down-regulating the type 2 inflammatory response.